W C Zamboni

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint An overview of the pharmacokinetic disposition of darbepoetin alfa
    William C Zamboni
    Department of Phamaceutical Services, School of Pharmacy, University of Pittsburgh, Pennsylvania 15213, USA
    Pharmacotherapy 22:133S-140S. 2002
  2. ncbi request reprint Control-relevant modeling of the antitumor effects of 9-nitrocamptothecin in SCID mice bearing HT29 human colon xenografts
    John M Harrold
    Department of Chemical and Petroleum Engineering, University of Pittsburgh School of Engineering, Pittsburgh, PA 15261, USA
    J Pharmacokinet Pharmacodyn 32:65-83. 2005
  3. ncbi request reprint Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors
    W C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, PA 15213, USA
    J Clin Oncol 18:3288-94. 2000
  4. ncbi request reprint Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15213, USA
    Invest New Drugs 26:399-406. 2008
  5. ncbi request reprint Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:7217-23. 2007
  6. ncbi request reprint Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 62:417-26. 2008
  7. ncbi request reprint Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes
    William C Zamboni
    Hillman Cancer Research Center, Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Invest New Drugs 24:393-401. 2006
  8. ncbi request reprint Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Cancer Res 11:4867-74. 2005
  9. ncbi request reprint Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Clin Cancer Res 10:5058-64. 2004
  10. ncbi request reprint Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 53:329-36. 2004

Detail Information

Publications36

  1. ncbi request reprint An overview of the pharmacokinetic disposition of darbepoetin alfa
    William C Zamboni
    Department of Phamaceutical Services, School of Pharmacy, University of Pittsburgh, Pennsylvania 15213, USA
    Pharmacotherapy 22:133S-140S. 2002
    ..Darbepoetin alfa, through its potential for less frequent dosing, offers a more convenient treatment option than r-HuEPO for patients with anemia secondary to cancer or kidney disease...
  2. ncbi request reprint Control-relevant modeling of the antitumor effects of 9-nitrocamptothecin in SCID mice bearing HT29 human colon xenografts
    John M Harrold
    Department of Chemical and Petroleum Engineering, University of Pittsburgh School of Engineering, Pittsburgh, PA 15261, USA
    J Pharmacokinet Pharmacodyn 32:65-83. 2005
    ..This methodology could then be used to aid the clinician in selecting dose levels and schedules, and extension to patient tailored treatment may eventually be feasible with this approach...
  3. ncbi request reprint Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors
    W C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, PA 15213, USA
    J Clin Oncol 18:3288-94. 2000
    ..We evaluated the pharmacokinetics and pharmacodynamics of docetaxel and topotecan when coadministered on two different sequences of administration...
  4. ncbi request reprint Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15213, USA
    Invest New Drugs 26:399-406. 2008
    ..We evaluated the tissue and plasma disposition of DB-67 lactone and hydroxy acid after administration of non-liposomal (NL) and liposomal (L) DB-67 in severe combined immunodeficient (SCID) mice...
  5. ncbi request reprint Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:7217-23. 2007
    ..For STEALTH liposomal formulations of anticancer agents to achieve antitumor effects, the active drug must be released into the tumor extracellular fluid (ECF)...
  6. ncbi request reprint Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 62:417-26. 2008
    ....
  7. ncbi request reprint Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes
    William C Zamboni
    Hillman Cancer Research Center, Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Invest New Drugs 24:393-401. 2006
    ..The aim of this study was to evaluate the functional consequence of known single nucleotide polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the pharmacokinetic disposition of 9NC and 9AC...
  8. ncbi request reprint Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Cancer Res 11:4867-74. 2005
    ..These results suggest that the intermittent schedule of 9-nitrocamptothecin may be an active regimen in patients with colorectal carcinoma...
  9. ncbi request reprint Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Clin Cancer Res 10:5058-64. 2004
    ..In an effort to increase the dose administered per day and determine whether the daily dose or number of days of treatment influence toxicity, we performed a Phase I study of 9NC using intermittent schedules of administration...
  10. ncbi request reprint Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 53:329-36. 2004
    ..Thus, we evaluated the disposition of encapsulated and released Pt in plasma and tumors after administration of STEALTH liposomal and nonliposomal cisplatin...
  11. ncbi request reprint Pharmacokinetics of pegfilgrastim
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, UPCI Research Pavilion, The Hillman Cancer Center, 5117 Centre Avenue, G 27C, Pittsburgh, PA 15213 1863, USA
    Pharmacotherapy 23:9S-14S. 2003
    ..Clinical trials have suggested that neutrophil-mediated clearance of pegfilgrastim may be self-regulating and may therefore be specific to each patient's hematopoietic recovery...
  12. ncbi request reprint Pharmacodynamic model of topotecan-induced time course of neutropenia
    W C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Biomedical Science Tower E 1040, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Clin Cancer Res 7:2301-8. 2001
    ..02 +/- 0.38 and 0.16 +/- 0.09, respectively (P < 0.05). The model estimate of ABC and the ratio of ABC to AUC(LAC) in children and NHPs may better reflect sensitivity to chemotherapy-induced neutropenia...
  13. ncbi request reprint The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid
    W C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh, Cancer Institute, Pennsylvania 15213, USA
    Ann Oncol 12:119-22. 2001
    ..In non-human primates, a 4-hour, as compared to a 30-minute, topotecan (TPT) infusion prolonged TPT exposure in the CSF...
  14. ncbi request reprint Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    L L Jung
    University of Pittsburgh Cancer Institute, PA 15213, USA
    Drug Resist Updat 4:152-67. 2001
    ..However, the optimal treatment regimens and administration schedules of these agents have yet to be established in clinical studies...
  15. ncbi request reprint Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA
    Cancer Chemother Pharmacol 57:631-9. 2006
    ..Thus, we evaluated the disposition of 9NC and 9AC after administration of 9NC under fasting conditions and after a standard meal...
  16. ncbi request reprint Concept and clinical evaluation of carrier-mediated anticancer agents
    William C Zamboni
    Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina, 3308 Kerr Hall CB 7360, 311 Pharmacy Lane, Chapel Hill, NC 27599 7360, USA
    Oncologist 13:248-60. 2008
    ..Future studies need to evaluate the mechanism of clearance of carrier-mediated agents and identify the factors associated with the pharmacokinetic and pharmacodynamic variability of carrier agents in patients and specifically in tumors...
  17. ncbi request reprint Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
    Ramesh K Ramanathan
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 55:354-60. 2005
    ..To improve the therapeutic index, we evaluated a weekly regimen of docetaxel in combination with capecitabine, and determined the maximum tolerated dose, toxicities and pharmacokinetics of this combination...
  18. ncbi request reprint Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck
    Sufi Mary Thomas
    University of Pittsburgh, 200 Lothrop St, W915 BST, Pittsburgh, PA 15213, USA
    Mol Pharmacol 73:627-38. 2008
    ..05). Combination of EGFR antisense oligonucleotides with low doses of docetaxel has antitumor efficacy, and it may be an effective treatment strategy for SCCHN...
  19. ncbi request reprint Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Cancer Invest 22:858-65. 2004
    ....
  20. ncbi request reprint Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 8:2992-9. 2002
    ..There was no relationship between Factor VIII expression and Pt exposure in tumors. The variable penetration of Pt from plasma into tumor ECF may be associated with variable response of tumors...
  21. ncbi request reprint Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    L L Jung
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Drug Resist Updat 4:273-88. 2001
    ..However, the optimal treatment regimens and administration schedules of these agents have yet to be established in clinical studies...
  22. ncbi request reprint Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor
    Clinton F Stewart
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 22:3357-65. 2004
    ....
  23. ncbi request reprint LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas
    Wesley N Sivak
    Department of Bioengineering, School of Engineering, University of Pittsburgh, Pittsburgh, PA, USA
    Acta Biomater 4:852-62. 2008
    ..These results clearly demonstrate the long-term, slow release of DB-67 from LDI-glycerol polyurethane discs and their potential for postoperative intracranial chemotherapy of cancers...
  24. ncbi request reprint Expression and activity of taxane-metabolizing enzymes in ovarian tumors
    Julie A DeLoia
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Magee Womens Research Institute, Pittsburgh, PA 15213, USA
    Gynecol Oncol 108:355-60. 2008
    ..The objective of this study was to determine whether ovarian tumors express genes regulating cellular efflux and subsequent metabolism, and whether any clinico-pathologic features correlated with expression...
  25. ncbi request reprint Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors
    Laura L Jung
    Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, PA 15213, Pittsburgh, USA
    Cancer Chemother Pharmacol 54:487-96. 2004
    ..Therefore, we evaluated the plasma pharmacokinetics and urine recovery of 9NC administered on three different schedules as part of phase I and phase II studies...
  26. pmc Endothelin receptor A blockade enhances taxane effects in prostate cancer
    Ardavan Akhavan
    Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Neoplasia 8:725-32. 2006
    ..This study demonstrates ABT-627 to have additive antitumor effects when used in combination with taxane drugs both in vitro and in vivo...
  27. ncbi request reprint Liposomal, nanoparticle, and conjugated formulations of anticancer agents
    William C Zamboni
    Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Cancer Res 11:8230-4. 2005
  28. ncbi request reprint Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma
    Robert A Parise
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, 15213, Pittsburgh, PA, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 783:231-6. 2003
    ..The LC-MS assay, which proved superior because of its greater sensitivity and relatively short (7 min) run time, should be an important tool for future pharmacokinetic analyses of docetaxel and paclitaxel...
  29. ncbi request reprint Catalyst-dependent drug loading of LDI-glycerol polyurethane foams leads to differing controlled release profiles
    Wesley N Sivak
    Department of Bioengineering, School of Engineering, University of Pittsburgh, Pittsburgh, PA, USA
    Acta Biomater 4:1263-74. 2008
    ..0x10(-8)). These results clearly demonstrate the long-term, catalyst-dependent release of DB-67 from LDI-glycerol polyurethane foams, indicating their potential for use in implantable drug-delivery devices...
  30. ncbi request reprint Pharmacokinetics after endovascular lung perfusion with Cisplatin
    Daniel B Brown
    Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Box 8131, St Louis, Missouri 63110, USA
    J Vasc Interv Radiol 17:883-8. 2006
    ..Endovascular lung perfusion (ELP) is a technique designed to deliver high doses of cisplatin via the pulmonary artery for the treatment of lung tumors. The purpose of the current study was to evaluate variables that affect adduct formation...
  31. ncbi request reprint A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors
    Victor M Santana
    Department of Hematology, St Jude Children s Research Hospital, University of Tennessee, Memphis, Tennessee 38103, USA
    Clin Cancer Res 9:633-40. 2003
    ..To assess the use of a pharmacokinetically guided topotecan strategy and evaluate the toxicity of protracted i.v. topotecan in children with recurrent solid tumors...
  32. ncbi request reprint A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
    ..The purpose of this Phase I trial was to determine the maximally tolerated systemic exposure (MTSE) of topotecan in combination with carboplatin and etoposide...
  33. ncbi request reprint Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors
    Marwan G Fakih
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Cancer Res 11:5942-9. 2005
    ..Docetaxel, cisplatin, and capecitabine are three active chemotherapeutic agents with different mechanisms of action. This phase I study investigated the feasibility and pharmacokinetics of this combination given on a weekly schedule...
  34. ncbi request reprint Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies
    James A Posey
    Department of Medicine, The University of Alabama at Birmingham, 263 Wallace Tumor Institute, 1530 3rd Avenue South, Birmingham, AL, USA
    Cancer Chemother Pharmacol 56:182-8. 2005
    ..The goal of this study was to determine the maximum tolerated dose of docetaxel and continuous infusion topotecan using two sequences of administration...
  35. ncbi request reprint Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model
    Daniel B Brown
    Mallinckrodt Institute of Radiology, Alvin J Siteman Cancer Center, St Louis, MO 63110, USA
    Oncol Rep 11:237-43. 2004
    ..Further study of ELP evaluating the acute and chronic effects of repeated treatment administration is warranted...
  36. ncbi request reprint A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma
    Kristopher J Kimball
    Division of Gynecologic Oncologic, University of Alabama at Birmingham, Birmingham, AL 35249 7333, USA
    Gynecol Oncol 111:95-101. 2008
    ....